



## Key Opinion Leader Luncheon: Targeting the antibody inhibitory checkpoint FcgRIIB to maximize cancer immunotherapy

Hosted by BioInvent International (BINV.ST)

The meeting will feature a presentation by Key Opinion Leader **Falk Nimmerjahn, PhD**, who will discuss “The role of Fc gamma receptors in regulating antibody-mediated anti-cancer immunity,” introducing the fundamental importance of these receptors in regulating the therapeutic activity of different types of anti-cancer mAbs.

BioInvent's management team will present the Company's clinical development strategy, highlighting its anti-FcgRIIB program, including the rationale to expand into solid cancer checkpoint inhibitor combinations, and the progress of its new clinical study for BI-1206. In July 2018, the FDA accepted BioInvent's IND application for a clinical study that will explore the activity of its proprietary monoclonal antibody BI-1206 in combination with rituximab for the treatment of patients with Non-Hodgkin lymphoma. BI-1206 is a monoclonal antibody that recognizes with high affinity and selectivity FcgRIIB (CD32B), the only inhibitory member of the FcgR family.

**Tuesday, Nov. 6, 2018**  
**12:00-1:30 pm EST**

**Lotte New York Palace**  
**455 Madison Ave**

### RSVP Information

This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited.

[Register](#)

### Webcast Information

For those who are unable to attend in person, a live webcast and replay will be accessible via the link here.

[Enter Webcast](#)

### Q&A Information

If you would like to ask a question during the live Q&A, please submit your request via the email link below.

[Email Q&A](#)

### KOL Biography

#### Falk Nimmerjahn, PhD

Dr. Nimmerjahn was trained in molecular biology, genetics and immunology at the Universities of Bayreuth, Erlangen-Nuremberg, and Munich, where he obtained his PhD. After postdoctoral training at the Helmholtz Centre Munich he joined Prof. Ravetch's laboratory in 2004, where he studied how different IgG subclasses mediate their activity in vivo and how IgG glycosylation impacts antibody activity. In 2007 he returned to Germany where he was appointed as an associate professor at the University Hospital of Erlangen and head of the laboratory of Experimental Immunology and Immunotherapy. In 2010 Falk Nimmerjahn was appointed as a full professor and chairman of the Institute of Genetics at the Friedrich-Alexander University of Erlangen-Nuremberg. He is the current head of the Department of Biology and Vice Dean of the Faculty of Natural Sciences at the FAU Erlangen-Nuremberg. His group has several major areas of interest, all focusing on a better understanding of how immunoglobulin G (IgG) antibodies work in mice and humans in vivo and how cellular Fc-receptors contribute to their activity. This includes in depth studies on the activity of therapeutic antibodies and studies deciphering the mechanisms of how self-reactive antibodies (autoantibodies) mediate tissue inflammation and destruction during autoimmune diseases. In addition to using a wide variety of classical inbred mouse models, his group develops novel humanized mouse models allowing to study human antibody activity on the background of an outbred human immune system in vivo. He published more than 150 papers in highest ranking peer reviewed journals, serves an editor for several textbooks and holds a variety of patents. Falk Nimmerjahn received several awards for his scientific contributions, including the Paul Ehrlich and Ludwig Darmstädter award for young scientists.